Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $839.53 million. The enterprise value is $793.92 million.
| Market Cap | 839.53M |
| Enterprise Value | 793.92M |
Important Dates
The last earnings date was Thursday, July 30, 2026, before market open.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 707.78 million shares outstanding. The number of shares has increased by 12.83% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 707.78M |
| Shares Change (YoY) | +12.83% |
| Shares Change (QoQ) | -10.56% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 21.21% |
| Float | 696.57M |
Valuation Ratios
The trailing PE ratio is 90.26 and the forward PE ratio is 42.62.
| PE Ratio | 90.26 |
| Forward PE | 42.62 |
| PS Ratio | 2.29 |
| Forward PS | 2.15 |
| PB Ratio | 3.10 |
| P/TBV Ratio | 5.90 |
| P/FCF Ratio | 24.43 |
| P/OCF Ratio | 23.97 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.15, with an EV/FCF ratio of 23.10.
| EV / Earnings | 85.36 |
| EV / Sales | 2.17 |
| EV / EBITDA | 24.15 |
| EV / EBIT | 31.31 |
| EV / FCF | 23.10 |
Financial Position
The company has a current ratio of 3.01, with a Debt / Equity ratio of 0.42.
| Current Ratio | 3.01 |
| Quick Ratio | 2.31 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 3.12 |
| Debt / FCF | 3.30 |
| Interest Coverage | 2.31 |
Financial Efficiency
Return on equity (ROE) is 3.65% and return on invested capital (ROIC) is 6.76%.
| Return on Equity (ROE) | 3.65% |
| Return on Assets (ROA) | 3.47% |
| Return on Invested Capital (ROIC) | 6.76% |
| Return on Capital Employed (ROCE) | 6.77% |
| Weighted Average Cost of Capital (WACC) | 4.72% |
| Revenue Per Employee | $900,440 |
| Profits Per Employee | $22,853 |
| Employee Count | 407 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.76 |
Taxes
In the past 12 months, Pharming Group has paid $6.54 million in taxes.
| Income Tax | 6.54M |
| Effective Tax Rate | 41.29% |
Stock Price Statistics
The stock price has increased by +1.20% in the last 52 weeks. The beta is 0.06, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | +1.20% |
| 50-Day Moving Average | 12.65 |
| 200-Day Moving Average | 15.32 |
| Relative Strength Index (RSI) | 47.58 |
| Average Volume (20 Days) | 21,094 |
Short Selling Information
The latest short interest is 19,179, so 0.00% of the outstanding shares have been sold short.
| Short Interest | 19,179 |
| Short Previous Month | 9,938 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 2.20 |
Income Statement
In the last 12 months, Pharming Group had revenue of $366.48 million and earned $9.30 million in profits. Earnings per share was $0.13.
| Revenue | 366.48M |
| Gross Profit | 317.09M |
| Operating Income | 25.35M |
| Pretax Income | 15.84M |
| Net Income | 9.30M |
| EBITDA | 32.88M |
| EBIT | 25.35M |
| Earnings Per Share (EPS) | $0.13 |
Balance Sheet
The company has $158.28 million in cash and $113.30 million in debt, with a net cash position of $44.99 million or $0.06 per share.
| Cash & Cash Equivalents | 158.28M |
| Total Debt | 113.30M |
| Net Cash | 44.99M |
| Net Cash Per Share | $0.06 |
| Equity (Book Value) | 270.49M |
| Book Value Per Share | 0.38 |
| Working Capital | 187.44M |
Cash Flow
In the last 12 months, operating cash flow was $35.03 million and capital expenditures -$660,000, giving a free cash flow of $34.37 million.
| Operating Cash Flow | 35.03M |
| Capital Expenditures | -660,000 |
| Depreciation & Amortization | 7.53M |
| Net Borrowing | -16.36M |
| Free Cash Flow | 34.37M |
| FCF Per Share | $0.05 |
Margins
Gross margin is 86.52%, with operating and profit margins of 6.92% and 2.54%.
| Gross Margin | 86.52% |
| Operating Margin | 6.92% |
| Pretax Margin | 4.32% |
| Profit Margin | 2.54% |
| EBITDA Margin | 8.97% |
| EBIT Margin | 6.92% |
| FCF Margin | 9.38% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.83% |
| Shareholder Yield | -12.83% |
| Earnings Yield | 1.11% |
| FCF Yield | 4.09% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 4.25% |
| EPS Growth Forecast (3Y) | 71.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 3.74 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.74 |
| Piotroski F-Score | 6 |